Testing Biomarkers in Gastroesophageal Adenocarcinoma (GEA)

There were ~1.6 million new cases of gastroesophageal cancers across the globe in 2018. This represents the seventh (esophageal) and fifth (stomach) most common cancers worldwide1

The frequency of overexpression of HER2 is slightly greater for cancers at the gastroesophageal junction in comparison to the stomach, and overexpression in the stomach varies by2:

  • Histologic type (more common in intestinal type than in diffuse type)2

  • Differentiation (more common in well and moderately differentiated tumors than in poorly differentiated tumors)2

Guideline-recommended sample preparation helps to improve test accuracy2

HER2

References

Microscope icon

Discover cancer biomarkers

Learn more about the importance of oncologic biomarkers and what they can tell you.

Molecular pathways icon

Explore molecular pathways

Learn more about the how cancer avoids immune response.